CLINICAL_TRIALS
trial_result
· 2024-11-19
Clinical Trial Update: Safety and Tolerability Study of AVID200 in Pts With Diffuse Cutaneous Systemic Sclerosis [Phase 1]
Summary
AVID200's Phase 1 safety and tolerability study in patients with diffuse cutaneous systemic sclerosis has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bristol-Myers Squibb | Conditions: Scleroderma, Diffuse | Phase 1 | Status: COMPLETED